EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Akso Health Group (AHG) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Akso Health Group $0.21, price $1.15, upside -81.7%, quality 17 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ADR · ISIN US98422P1084

AH Akso Health Group logo Thin data Oct 3, 2026

Akso Health Group

AHG · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.2100 · Strongly overvalued (−81.7%)
!Quality 17/100
!Weak Growth (revenue 3y +1.6 %/yr)
!Loss-making · -135.0% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (0/10)
!Narrow moat 7/100
!Evidence only low, so the estimate is less certain
Watch Akso Health Group ADR for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$18.87 $0.2505 Fair Value $0.2100 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range $0.2505 – $18.87 · fair‑value band $0.1400 – $0.2600 · the $1.15 price screens above the $0.2100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.

Follow Akso Health Group ADR in your weekly email

Every Wednesday you see whether Akso Health Group ADR is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Akso Health Group, together with its subsidiaries, operates a social e-commerce mobile platform in the People's Republic of China.

Show more

Akso Health Group, together with its subsidiaries, operates a social e-commerce mobile platform in the People's Republic of China. It operates Xiaobai Maimai App, a social e-commerce mobile platform that offers food and beverage products, wine, cosmetic products, fashion and apparel, entertainment products, housewares, home appliances, and cost-saving promotions at petrol gas stations. The company also sells medical devices, such as defibrillators and anesthesia laryngoscopes. In addition, it provides health treatment, consultancy support, and marketing promotion services, as well as technological promotion services and import and export. The company was formerly known as Xiaobai Maimai Inc. and changed its name to Akso Health Group in December 2021. Akso Health Group was founded in 2014 and is headquartered in Qingdao, China.

Stock analysis

Akso Health Group ADR (AHG) currently trades at $1.15, while our model-based Fair Value estimate is $0.2100, 81.7% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $0.1400 (bear) to $0.2600 (bull), the price of $1.15 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 17/100 (below-average quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

Akso Health Group ADR reported revenue of $13.8M in FY2026 versus $6.3M in FY2022, a compound +21.7%/yr. Reported net income was −$18.7M in FY2026.

Key figures

Market cap $831M · P/S ratio 63.2 · EPS (TTM) $−0.0300 · Net margin −135% · Return on equity −9.9% · Return on assets (EBIT) −37.0% · Operating margin −37.5% · Revenue (TTM) $13.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 54% below its 52-week high and 66% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 37% fair-value upside, at −82%, AHG screens richer than that median.

Fair Value models

Bear $0.1400 Fair Value $0.2100 Bull $0.2600
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.1100 $0.1400 $0.2100 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.1100 $0.1400 $0.2100 54

Open the full fair value analysis →

Notify me when AHG reaches fair value

Put AHG on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 17/100

Of which business quality 23 · Market factors (momentum, volatility) 21

Profitability 0
Margins and returns on capital today
Quality Growth 55
Are margins and returns improving?
Cashflow 4
Earnings quality: real cash, not paper profit
Fin. Strength 74
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 6
Price trend over the last 3–12 months (market factor)
52W Momentum 13
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−6.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,547.1% (2021) → −28.9% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

AHG screens overvalued: fair value 82% below the price. Compare with McKesson Corporation →

Compare Akso Health Group ADR with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 78 stocks

Beats the industry median on 0/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 24 · Bottom 25%
Fair Value upside −84.5% · Bottom 25%
Profitability
Return on assets −1.2% · Bottom 25%
Net margin (TTM) −135.0% · Bottom 25%
Operating margin (TTM) −37.5% · Bottom 25%
Growth and dividend
Revenue growth −12.9% · Bottom 25%
Balance sheet
Debt / equity 0.11× · Above median

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/B 4.59× · Priciest 25%
P/S (TTM) 60.09× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 45
FUTURE (revenue growth)0 · sector 13
PAST (return on equity)0 · sector 28
HEALTH (low debt)94 · sector 97
DIVIDEND (yield)0 · sector 58

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
McKesson Corporation MCK $864.82 $822.74 −5%
Cencora, Inc COR $309.78 $215.20 −31%
Cardinal Health, Inc CAH $220.29 $162.84 −26%
Henry Schein, Inc HSIC $86.37 $76.77 −11%
Shanghai Pharmaceuticals Holding 601607 ¥16.02 ¥42.67 +166%
Sinopharm Group 1099 HK$14.88 HK$55.77 +275%
Galenica AG GALE CHF 82.55 CHF 61.79 −25%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.39 ¥26.64 +37%
Jointown Pharmaceutical Group 600998 ¥5.05 ¥9.84 +95%
China National Medicines Corporation 600511 ¥25.80 ¥58.47 +127%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Akso Health Group ADR · Fair Value
$0.2100 −82%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Akso Health Group ADR Fair Value". https://www.fairvalue-calculator.com/stock/AHG

Frequently asked questions

Is Akso Health Group (AHG) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $0.2100 versus a price of $1.15, about −82% upside (overvalued).
What is the fair value of AHG?
Our model-based fair value for Akso Health Group ADR is $0.2100 (as of Oct 3, 2026), built from audited fundamentals. The current price: $1.15.
What is the quality score of AHG?
Akso Health Group ADR has a Quality Score of 17/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Akso Health Group (AHG)?
Our model-based price target is the fair value of $0.2100 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario $0.1400, optimistic scenario $0.2600. It is a calculation from audited fundamentals, not an analyst target.
What is the Akso Health Group ADR stock forecast for 2026?
Our models put fair value at $0.2100, about −82% upside versus a price of $1.15 (overvalued). Cautious scenario $0.1400, optimistic scenario $0.2600. The calculation is refreshed regularly with new filings.
What is the revenue of Akso Health Group (AHG)?
Akso Health Group ADR reported trailing-twelve-month revenue of about $13.8M (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Akso Health Group (AHG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Akso Health Group ADR it is $0.2100 per share (as of Oct 3, 2026), against a price of $1.15. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Akso Health Group ADR stock overvalued or undervalued in 2026?
As of Oct 3, 2026, AHG trades above its calculated fair value: price $1.15, fair value $0.2100, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AHG?
No. The price is what the market pays today ($1.15); the fair value is what the company's own numbers justify ($0.2100). For Akso Health Group ADR the two are $0.9400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Akso Health Group ADR worth?
The market values Akso Health Group ADR at about $831M (market capitalisation, as of Oct 3, 2026). Per share that is $1.15; our models calculate a fair value of $0.2100 per share.
What do the bullish and bearish scenarios say about AHG?
Our models span a range for Akso Health Group ADR: cautious scenario $0.1400, base $0.2100, optimistic $0.2600 per share (as of Oct 3, 2026, price $1.15). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Akso Health Group (AHG)?
Balance-sheet figures for Akso Health Group ADR (as of Oct 3, 2026): return on equity −9.9%, debt of 0.11 per unit of equity. They feed the Quality Score of 17/100, which measures business quality independently of the share price.
How far is AHG from its 52-week high?
Akso Health Group ADR trades at $1.15, about 54% below its 52-week high of $2.50 and 66% above the low of $0.6910 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2100 is for.
Which stocks are comparable to Akso Health Group ADR?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Akso Health Group ADR stock attractive at the current price?
The data as of Oct 3, 2026: price $1.15, calculated fair value $0.2100 (−82%), Quality Score 17/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AHG calculated?
We run Akso Health Group ADR through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2100, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Akso Health Group ADR itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Akso Health Group (AHG)?
The closing price on Oct 2, 2026 was $1.15. Our model-based fair value is $0.2100, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Akso Health Group ADR right now?
The price sits above even our optimistic bull case ($0.2600). The favourable scenario is already priced in. Weak quality (17/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1400 to $0.2600) leaves room in how you read the outcome.

Key figures of Akso Health Group ADR

How large is the market capitalisation of Akso Health Group (AHG)?
The market capitalisation of Akso Health Group ADR is $831M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Akso Health Group (AHG)?
The price-to-sales ratio of Akso Health Group ADR is 63.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Akso Health Group (AHG)?
Earnings per share at Akso Health Group ADR are $−0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Akso Health Group (AHG)?
The net margin of Akso Health Group ADR is −135% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Akso Health Group (AHG)?
The return on equity (ROE) of Akso Health Group ADR is −9.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Akso Health Group (AHG)?
On an EBIT basis the return on assets of Akso Health Group ADR is −37.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Akso Health Group (AHG)?
The operating margin of Akso Health Group ADR is −37.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Akso Health Group (AHG)?
Revenue at Akso Health Group ADR is growing −12.9% versus a year earlier (3y avg +1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Akso Health Group (AHG) generate?
The free cash flow of Akso Health Group ADR is −$188M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Akso Health Group (AHG) carry?
The net debt of Akso Health Group ADR is $205K (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Akso Health Group ADR in the live analysis

One click puts Akso Health Group ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.